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COMMENTS
Population-Based Genetic Studies:

Informed Consent and Confidentiality

Michael J. Smitht

I.

INTRODUCTION

Leonore Wexler was diagnosed with Huntington's disease in
1968.1 She was not the first member of the Wexler family to be
diagnosed. Her daughter, Nancy, had already witnessed several other
relatives succumb to this devastating disease, but it was her mother's
diagnosis that spurred Nancy to action.2 She set forth on a journey to
discover the genetic cause of Huntington's disease. 3
Nancy's search led to a remote region of Venezuela, near Lake
Maracaibo where she and her team found one family that suffered an
extremely high incidence of Huntington's disease. 4 By meticulously
mapping the genealogy of that family, including thousands of
members stretching back over 100 years, and working closely with
genetic researchers, in 1993 Nancy and her team eventually identified
the specific gene, and the mutation in that gene, associated with
Huntington's disease.5
t
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I See ALICE WEXLER, MAPPING FATE: A MEMOIR OF FAMILY, RISK, AND GENETIC
RESEARCH, 42-65 (1996).
2 See id. at 85-102.
See id. at 125-5 1.
See id. at 182-209.
See id at 210-61.
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The long and arduous path taken by Nancy Wexler and her
colleagues has since opened the door to the discovery and mapping of
numerous other disease genes. 6 The goals remain consistent but the
pace of discovery has increased rapidly. On February 12, 2001, a full
two years earlier than expected, researchers with the Human Genome
Project announced that a rough map and sequence of the entire human
genome had been completed.7 Technological strides arising from the
Human Genome Project promise to change the face of science, and
the face of humanity.
Interpretation of the human genome promises a wealth of
benefits to humanity including accurate genetic testing and more
effective therapies and treatments for genetic diseases.8 As with other
technologies, such progress comes at a price. A myriad of concerns
has surfaced surrounding genetic research and the possible misuse of
genetic technology.
Those concerns include: fears of genetic
discrimination in insurance 9 and employment;' 0 regulation of genetic
therapy directed at reproductive cells, which could influence future
12
generations;" issues related to reproductive choices and autonomy;
assuring equal access to genetic technology between the rich and the
poor;13 and genetic enhancements, including human cloning.14
6

See generally Gerardo Jimenez-Sanchez et al., Human Disease Genes, 409 NATURE

853, 853-55 (Feb. 15, 2001); Leena Peltonen & Victor A. McKusick, Dissecting Human
Diseases in the Postgenomic Era, 291 SCIENCE 1224, 1224-29 (Feb. 16, 2001).
7 The major scientific journals SCIENCE and NATURE both devoted full
issues to the
announcement and publication of the Human Genome. See generally 291 SCIENCE 1145 (Feb.
16, 2001); 409 NATURE 745 (Feb. 15, 2001).
See also International Human Genome
Sequencing Consortium, Initial Sequencing andAnalysis of the Human Genome, 409 NATURE
860, 872 fig.9 (Feb. 15, 2001) (providing a detailed map of the draft human genome)
[hereinafter IHGSC].
8 See generally MAXWELL J. MEHLMAN & JEFFERY R. BOTKIN, ACCESS TO THE
GENOME: THE CHALLENGE TO EQUALITY 21-34 (1998) (providing a discussion of the various
means of genetic testing and gene therapies either currently employed or researched for future
use).
9 See generally Mark A. Rothstein, The Use of Genetic Testing Information
for
Nonmedical Purposes, 9 J.L. & HEALTH 109, 113 (1995) (discussing potential nonmedical uses
and abuses of genetic information).
10 See id. at 111.
II See MEHLMAN, supra note 8,
at 32-34.
12 See id. at 51.
13 See generally Mark A. Rothstein & Sharona Hoffman, Genetic Testing, Genetic
Medicine, and Managed Care, 34 WAKE FOREST L. REV. 849 (1999) (discussing the role of
managed care organizations in the administration of genetic medicine). See also MEHLMAN,
supra note 8, at 85-102 (providing a detailed discussion of the potential hurdles related to
insurance availability and the ability to pay for genetic testing and genetic therapies).
14 See MEHLMAN, supra note 8, at 34-37.
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Despite the current achievements, understanding the full human
genome requires a great deal of additional research into deciphering
the complex instructions hidden in our DNA. 15 Virtually every cell in
a human body contains the full set of instructions necessary to create
that particular individual.' 6 These instructions are encoded in twenty17
three pairs of individual DNA strands known as chromosomes.
These chromosomes carry over 30,000 encoded genes. 1 8 Each gene
performs a specific function, some may perform several, but the
functions of only a few genes are currently understood. 19 The Human
Genome Project has provided a map of chromosomes, but complete
understanding of the functions of each and every gene will be
achieved through the use of other research approaches.
One
necessary approach is population-based genetic studies: studies that
rely on the large-scale collection of genetic, genealogical, and
medical data from thousands of individuals.2 °
Population-based genetic studies come with their own set of
concerns. Connecting the DNA sequences of individual genes within
the human genome to the various diseases and traits for which they
encode will require thousands, even millions, of individual research
subjects. 2' Such research requires the divulgence of information that
22
strikes at the very core of our most intimate and private lives.
Research participants' DNA samples will be collected, genealogical
histories of their families gathered, and their confidential, individual
15 See Ewan Birney et al., Mining the DraftHuman Genome, 409 NATURE 827 (Feb. 15,
2001).

See MEHLMAN, supra note 8, at 10.
Id.
18 Estimates on the potential number of genes in the human genome have varied widely
16

over the past several decades. The International Human Genome Sequencing Consortium has
now estimated, based on the rough draft of the genome published in February 2001, that there
are approximately 30,000 human genes. However, this number may be misleading, as complex
cellular processing of genes and gene products may result in several possible products from a
single gene sequence. Therefore, one gene may have several possible functions based on factors
such as cell type or tissue type where the gene is expressed at a given time. See generally
IHGSC, supra note 7, at 898-99.
19

See MEHLMAN, supra note 8, at 11.

See also NATIONAL INSTITUTES OF HEALTH,

OMIM: ONLINE MENDELIAN INHERITANCE IN MAN, at http://www.ncbi.nlm.nih.gov

(last

visited Oct. 27, 2001) (providing an on-line resource for researching various human diseases
and their known associated diseases).
20 Henry T. Greely, Iceland's Planfor Genomics Research: Facts and Implications, 40
JURIMETRICS J. 153, 157 (1999); John A. Robertson, Privacy Issues in Second Stage Genomics,
40 JURIMETRICS J. 59, 60 (1999).
21 Greely, supranote 20, at 157.
22 Robertson, supra note 20, at 61.
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medical records scrutinized. 3 In order to find willing participants for
privacy-invasive research, two major issues must be addressed:
informed consent and confidentiality of research records.
This Comment explores several of the proposed and ongoing
population-based studies in Iceland, Estonia, Italy, Britain, and the
United States. Guidelines that have been drafted for two of these
studies will be analyzed against a background of international law
relating to informed consent and confidentiality in regard to medical
research. Part II provides a brief overview of the Human Genome
Project and details the reason population-based genetic studies are
necessary. Part III explores several of the proposed and ongoing
population-based genetic studies around the world. Part IV provides
a framework of international law against which these projects should
be analyzed. Part V focuses on an analysis of two specific projects, in
Iceland and in Estonia, and compares the national laws authorizing
these projects against the international laws discussed in Part IV.
Finally, Part VI concludes with recommendations designed to
properly balance the legitimate research goals of population-based
genetic studies with the individual rights of the research subject.
II. THE HUMAN GENOME PROJECT

The twenty-three pairs of chromosomes found in each human
cell contain over three billion bits of information written in the fourletter nucleotide alphabet of A, C, G, and T.24 This mass of
biochemical information provides the genetic blueprint necessary to
create a human being. If these strings of As, Cs, Gs and Ts found in
the chromosomes were printed in a readable form, the information
would resemble a book written in a foreign language with no spacing
or punctuation. 25 This complete book of information is known as the
genome.26 A trained researcher begins deciphering this book by
recognizing identifiable patterns and then inserting the punctuation
23
24

Id. at 60-6 1.
Adenine, Cytosine, Guanine, and Thymine are the four basic nucleotides that

assemble to form the DNA double helix. In that structure, Adenine pairs with Thymine and
Cytosine pairs with Guanine. See generally MEHLMAN, supra note 8, at 10 (providing an easyto-read explanation of the basics of DNA and genes); David Baltimore, Our Genome Unveiled,
409 NATURE 814 (Feb. 15, 2001) (providing an overview of genomics and a glossary of
common terms used in genomic research).
25 Actually, in written form, the three billion individual letters would "fill tomes
equivalent to 200 New York City phone books." Elizabeth Pennisi, The Human Genome, 291
SCIENCE 1177, 1178 (Feb. 16, 2001).
26 Baltimore, supra note 24, at 815.
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necessary to create coherent sentences.27 Each of these individual
sentences represents a single gene. Each gene ultimately, alone or in
conjunction with others, performs one or more functions within the
human body.28 A mistake in a gene, even the misspelling of one letter
in a sentence, often results in disease.29 Understanding the individual
functions and complex interactions of each gene provides vital
information researchers can use to detect and potentially correct
genetic defects.3 °
But how do researchers, faced with just the basic DNA
nucleotide sequence of As, Cs, Gs, and Ts, make sense of it all in
Traditionally, researchers began by
terms of human disease?
recognizing some malfunction within a diseased cell. Through
diligent research, perhaps a basic defect in a gene, known as a
mutation, could be isolated. Working with model organisms, a
researcher compared the mutant organisms to normal, "wild-type,"
organisms. Through extensive study, the researcher attempted to
determine biochemical and genetic differences between the mutant
and the wild-type organism and would eventually try to link the
disease phenotype, or the physical manifestation of the mutation, to a
mutant genotype, or genetic background. Further study often led to
identification of the exact mutation in a single gene. Some mutations
result from insertions or deletions of nucleotides within the gene,
similar to adding or removing letters from a sentence. Other
mutations result from just a single misspelling, for example a simple
switch of one nucleotide from A to C, within a gene.
For several reasons, however, this method of research provides
only limited results. First, it relies upon the existence of a defect that
can be easily isolated and analyzed.3' Some mutations may be
virtually undetectable by traditional means, or the effect of the
mutation may be so slight as to go unnoticed in traditional genetic or
biochemical studies. 32 Second, it is laborious and time-consuming,
and if more than one gene is involved, the goal becomes much more
difficult to achieve.33 Third, environmental and other factors may
influence the particular role of a gene in the body, which complicates
27

28
29

30
31

See MEHLMAN, supra note 8, at 7-19.
See id.
Id. at 12.
Id. at 42-65.
Id. at 13.

32

Id.

33

MEHLMAN, supra note 8, at 17.
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the analysis even further.34 Consequently, more efficient methods of
determining the role of the genes in human disease are necessary in
order to move forward from the map provided by the Human Genome
Project to a full understanding of genetic function and disease
pathology at the cellular and molecular level.
A.

Goals of the Human Genome Project

The Human Genome Project, launched in 1990, represents a
long-term, multibillion dollar effort to sequence and map the entire
human genome in an effort to provide researchers with a different
starting point from which to approach genetic studies: the genes
themselves.36
Traditional research methods have relied on the
existence of a detectable physical manifestation caused by an
underlying genetic defect. The sequence developed through the
Human Genome Project allows genes to be analyzed in the absence of
clear physical manifestations. Researchers will be able to study
normal genes in the laboratory, and manipulate the sequence of those
genes to determine their basic function rather than relying on the
existence of potentially elusive mutations.37 However, even with the
full sequence in hand, a large amount of research will still be needed
before researchers can completely understand how genes interact with
one another and external factors. Subsequent studies stemming from
the Human Genome Project will be responsible for linking individual
genes or groups of genes to specific human diseases and traits.38
Currently, over 5,000 human disorders are known to have a
genetic basis and over 1,000 of those disorders have been mapped to
specific regions of the genome. 39 For some diseases, genetic linkages
have already been identified and genetic tests developed to determine
whether an individual actually carries a defective gene responsible for
those diseases. 40 Genetic tests are currently available for a variety of
diseases including Lou Gehrig's disease (amyotrophic lateral sclerosis
or ALS), Alzheimer's, ataxia, cystic fibrosis, Down's syndrome,
Id.
35 See Peltonen, supra note 6.
36
MEHLMAN, supra note 8, at 13-15. See also Leslie Roberts, Controversialfrom the
Start, 291 SCIENCE 1182 (Feb. 16, 2001) (detailing the history of the Human Genome Project).
37 MEHLMAN, supra note 8, at 13. See also Peltonen, supra
note 6.
38 Robertson, supra note 20, at 60. See also Birney, supra

note 15.

39

Rothstein, supra note 13, at 854.

40

U.S. DEPT. OF ENERGY, HUMAN GENOME PROJECT INFORMATION: GENE TESTING, at

http://www.oml.gov/hgmis/medicine/genetest.html (last modified Sept. 17, 2001).
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hemophilia A and B, Huntington's disease, muscular dystrophy,
phenylketonuria (PKU), Tay-Sachs disease, and several forms of
inherited cancers. 4 1 These genetic tests are performed using a variety
of methods: prenatal screening for inherited diseases, neonatal
screening for metabolic conditions that could benefit from early
diagnosis and treatment, clinical screening of children and adults who
may be at risk for certain genetic diseases, and carrier screening to
determine whether an individual carries a single copy of a recessive
defect which could be passed on to his or her children.42
Unfortunately, most of these tests are useful for diagnostic purposes
only.
In a smaller number of cases, genetic linkages have been used to
begin development of therapies designed to control or correct the
genetic defect.4 3 However, the path between the basic gene sequence
and new therapies can be extremely complicated and requires analysis
of massive amounts of data. 44 As the number of genes and other
outside factors involved in a given condition increases, the
complexity of the study necessary to understand that condition also
increases, as does the amount of data needed to achieve a meaningful
result.45 Ultimately, to understand fully the range of functions hidden
in the myriad of gene sequences provided by the Human Genome
Project, researchers will need to study genes and gene interactions at
both the cellular and the population levels.
B. The Needfor Population-BasedGenetic Studies
DNA provides a basic code that must be deciphered by the
scientific community before it can be diagnostically and
therapeutically exploited. In order to develop accurate genetic tests
and effective gene therapies, the DNA sequences of the individual
genes must be correlated with the physiological and phenotypic
effects that result from that sequence. Some diseases arise due to a
mutation in only one gene. These "monogenic" diseases include
41

Id. See also Lawrence 0. Gostin & James G. Hodge, Jr., Genetic Privacy and the

Law: An End to Genetic Exceptionalism, 40 JURIMETRICS J. 21, 26 (1999).
42 Gostin, supranote 41, at 26. See also MEHLMAN, supra note 8, at 42-65.
43

U.S. DEPT. OF ENERGY, HUMAN GENOME PROJECT INFORMATION: GENE THERAPY,

at http://www.oml.gov/hgmis/medicine/genetherapy.html (last modified Sept. 17, 2001). See
also MEHLMAN, supranote 8, at 29-34.
44 Robertson, supra note 20, at 60; Greely, supra note 20, at 157. See also Peltonen,
supranote 6.

45

See Robertson, supra note 20, at 60. See also Peltonen, supranote 6.
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sickle cell anemia, cystic fibrosis, Huntington's disease, and
Duchenne muscular dystrophy.46 If mutations in two or more genes
interact to cause the disease pathogenesis, the disorder is
"polygenic. ' '47 There is also a third class, "multifactorial" diseases,
which result from complex interactions between genetic mutations
and various environmental factors.48 In many cases it is difficult to
distinguish between polygenic and multifactorial disorders, but these
two categories account for a vast range of human disorders including
heart disease, diabetes, asthma, schizophrenia, and various cancers.4 9
Interestingly, some disorders develop despite the absence of any
recognizable genetic defect in a particular patient. While there are
known genetic linkages to Alzheimer's disease, there are some
patients who have been diagnosed with Alzheimer's who do not carry
any of the known mutations associated with the disease.50 For
Alzheimer's disease, three classes of patients have been found. 51 In
the first class are those individuals who carry a particular set of
genetic mutations that make it almost certain they will develop the
disease. However, such individuals account for less than 5% of all
Alzheimer's patients. 2 In the second class, which accounts for
between 30% and 60% of Alzheimer's patients, the individuals carry
some genetic mutations, but other known genetic linkages test as
normal 3
In this class, the risk of contracting Alzheimer's is
increased, but not certain. Finally, a group of patients has developed
Alzheimer's even though it carries none of the known mutations
associated with the disease.54
The degree to which a mutated defect is expressed is referred to
as "penetrance.",55
For some disorders, especially monogenic
disorders such as Huntington's disease, penetrance is virtually 100%,
meaning that an individual possessing the mutated gene will

46

MEHLMAN, supra note 8, at 17.

Id. at 17-18.
Id. at 18. See also Rothstein, supra note 13, at 854-55.
49 MEHLMAN, supra note 8, at
18.
47
48

See Sarah Tobin et al., The Genetics of Alzheimer Disease and the Application
of
Molecular Tests, 3 GENETIc TESTING 37 (1999).
51 See id. at 37-38.
50

52

Id.
53 See id. at 37.
54 See id at 37, 40.
55 See Rothstein, supra note 13, at 855
n.36.
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eventually become symptomatic.56 In polygenic and multifactorial
disorders, however, penetrance may be greatly affected by other
factors and thus decreased. For example, the penetrance of mutations
in the BRCA1 gene associated with breast cancer is approximately
55% which means that 45% of women who test positive for the
mutation will never develop breast cancer. 57 This indicates that the
BRCA1 gene is not the only determinative factor in breast cancer.
There are likely to be other genes, environmental factors, or a
combination of both, that interact with the BRCA1 gene and affect its
penetrance.5 8 In order to appreciate more fully the role of BRCA1
mutations in breast cancer, these other factors must be unveiled.
When Nancy Wexler and her colleagues tracked down the
genetic link for Huntington's disease, the study relied upon the
gathering of data concerning several thousand family members
located around Lake Maracaibo in Venezuela. 59 By studying genetic
and genealogical data from both affected and unaffected individuals,
the team was able to track down the genetic basis for Huntington's
disease. One reason for the success of the study is that Huntington's
disease is a disorder that has now been traced to a single gene that
exhibits almost 100% penetrance. 60 In order to correlate the various
factors that play a role in the complex interactions found most
prominently in polygenic and multifactorial diseases, analysis of the
DNA sequence in light of personal medical histories and genealogical
data is necessary.6 ' Such analysis allows researchers to understand
better the effect of a given DNA sequence on the health of an
individual person, members of that person's family, and the larger
population in which that person resides. The more complex the
interactions between multiple genes, or between genes and other
environmental factors, the greater the amount of data that will be
needed for analysis. In some cases, information from thousands or
even millions of individuals will need to be analyzed to comprehend
fully the complexities of a particular disease pathogenesis.62
Population-based genetic studies are designed to facilitate exactly the
56

See MEHLMAN, supra note 8, at 17.

57

Rothstein, supra note 13, at 855-56.

58
59

Id.
See WEXLER, supra note 1, at 182-209.

60
61

See MEHLMAN, supra note 8, at 17.
Robertson, supra note 20, at 60.
Greely, supranote 20, at 157.

62
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and

III. CURRENT PROPOSALS FOR POPULATION-BASED GENETIC
STUDIES
The quest to identify populations well suited for large scale
genetic analysis has already begun. One commentator has identified a
list of several factors that make a population attractive to the research
community, although these factors by no means create an exhaustive
list. 63 First, the population should be large enough to provide
meaningful information, yet small enough to be manageable for the
researchers. 64 Second, there should be well-documented genealogical
data throughout the population so that researchers may identify and
trace familial patterns.65 Third, genetic data will be of little use unless
there is also a good medical history that can be used to trace the
progression of conditions in a given individual.66
Fourth, the
population should be fairly homogenous, meaning the basic genetic
background of all individuals in the study should be fairly
consistent. 67 Homogeneity may be found where a population has
enjoyed relative isolation over long periods of time. Such isolation
also ensures that most of the members of the population have
experienced similar environmental conditions. Finally, researchers
want populations that strongly support medical research to ensure the
widest possible participation from the residents.6 8 Based on these
criteria, several candidate populations have already been identified
and population-based genetic studies have been proposed.
A.

Icelandand deCode Genetics

One of the most noted and advanced studies is based in Iceland.
First, the Icelandic population of 275,000 inhabitants, spread over
roughly 40,000 square miles of land, is a manageable size for
researchers. 69 This population is large enough that several diseases
may be found in many different individuals, yet small enough in both
63
64
65
66
67
68
69

Id. at 159-60.
Id.
Id.
Id.
Id. at 160.
Greely, supra note 20, at 159.
Id.
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population and area that it should be fairly easy to gather and enter all
the necessary data to make studies fruitful. Second, Iceland has a rich
genealogical tradition; many Icelanders have traced their family roots
back to the fourteenth century and beyond.70 It is well known that
genetic variation within a family is much lower than in the general
population. Against a backdrop of genetic similarities within the
family, mutations that may be correlated with a disease stand out
more readily. Third, Iceland maintains a universal public health
system dating back to 1915.71 In addition, since about 1945, there has
been a centralized collection and preservation system for tissue
samples.72 Thus, the Icelandic public health system provides the
research community with strong medical history data for almost the
past 100 years. Fourth, Iceland has remained relatively isolated.
Aside from its indigenous inhabitants, Iceland has received few
immigrants.7 3 This means Iceland has a comparatively homogenous
genetic pool that has been exposed to very similar environmental
influences over its history. Finally, Icelandic citizens demonstrate a
willingness to participate in medical research, a willingness bolstered
by strong government support of such research efforts.74
In 1997, Kari Stefansson, Chief Executive Officer of deCode
Genetics, approached the Icelandic government with a proposal to
create a centralized database constructed of genetic information of the
entire Icelandic population.75 The Icelandic parliament, the Althing,
saw great potential in allowing such a database to be created. The
Althing had discussed plans to centralize and computerize the
national health records of its inhabitants in order to improve health
care throughout the nation. 76 That plan, however, had been delayed
for financial reasons.77 With active participation from deCode, both
legislatively and financially, the plan once again became feasible.
Beyond the potential scientific benefits realized through such a
project, the Althing also believed that the creation of the database
70

Id.

71
72

Id.
Id.

73 Id. at 160.
74

Greely, supranote 20, at 159.

Hr6bjartur J6natansson, Iceland's Health Sector Database:A Significant Head Start
in the Search for the Biological Grail or an Irreversible Error?, 26 AM. J.L. & MED. 31, 37
75

(2000). See also Greely, supra note 20 (providing a detailed account of the history of deCode
Genetics and its role in Iceland).
76

See J6natansson, supranote 75, at 37.

Id.
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would provide Icelandic scientists and scholars with employment,
allowing them to stay in Iceland rather than seek other opportunities
abroad. 8 However, while generally approving of the deCode project,
the Althing expressed some reservations regarding the potential
private "ownership" and "control" of Icelandic medical records
created through efforts of the public health system using public
funding by a private entity.7 9
In December of 1998, the Althing passed the Act on a Health
Sector Database that authorized the creation of a national database
consisting of genetic, 80
genealogical and medical history data of all
inhabitants of Iceland.
The Act provides that the database be
operated by a licensee for terms of no greater than twelve years at a
time, subject to the Act and special license agreements. 81 Not
82
surprisingly, the first licensee of the database is deCode Genetics.
Specific provisions and conditions of the Act and the resulting
regulation designed to control operation of the database will be
discussed in more detail in Section V.
B. Estonian Gene Bank
While the Icelandic project is the furthest along, similar projects
are at various stages of development throughout the world. In 1999,
Estonia created the Eesti Geenikeskus, or Estonian Genome
Foundation, which plans to create the Estonian Gene Bank.83 Unlike
Iceland, Estonia is not an isolated population with a fairly
homogenous gene pool. 84 Nevertheless, Estonians are genetically
similar to inhabitants of mainland Europe. Therefore, Estonia's larger
population will facilitate the detection and study of rare diseases
expressed in a very small number of individuals. 85 A draft proposal
78 Id. at40.
79 Id. at 57-58.
80 Act on a Health Sector Database No. 139/1998 (1998)
http://govemment.is/interpro/htr/htr.nsf/pages/gagngr-log-ensk

(Dec.

17,

(Ice.), available at
1998)

[hereinafter

Health Sector Database Act].
81 Id. arts. 4-5.
82

Ruth Chadwick, The kelandic Database-DoModern Times Need Modern Sagas?,

319 BMJ 441 (Aug. 14, 1999), available at 1999 WL 10992324 and at http://www.bmj.com.
83 Jaclyn M. Sindrich, Genome Project Unique in the World, BALTIc TIMES, Aug. 9,

2000, available at 2000 WL 8508639. See also Eesti Geenikeskus [Estonian Genome
Foundation], at http://www.genomics.ee (last modified Sept. 20, 2001) (providing updates on
the project and links to recent press releases).
84
85

Lone Frank, Biotechnology in the Baltic, 19 NATURE BIOTECH. 513, 514 (June 2001).

Id
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on the project was presented to the Ministry of Social Affairs in April
2000 and the Human Genes Research Act was passed in December
2000.86 Specific provisions of the Act will be discussed in Section V,
but it is expected that about one half of the funding necessary will be
provided by the government with the remainder supplied by
companies wishing to have access to the information.87 In fact, the
Estonian Genome Foundation launched a website in November 2000
to attract investors to its project. 88 When completed, the government
hopes the database will contain DNA 8and
medical records of at least
9
two-thirds of the 1.4 million Estonians.
C. ProposedStudies in the United Kingdom, Italy, and Tonga
In the United Kingdom, the British Medical Research Council
and the Wellcome Trust announced plans to begin construction of a
national gene bank beginning in early 2001.90 The initial program,
known as the UK Population Biomedical Collection, will collect
DNA samples and medical histories from approximately half a
million patients in selected clinic and physician practices. 9' It is
expected that this initial phase will eventually lead to a complete
national database that can be used to aid in medical research.9 2
In October 2000, ten remote villages grouped in southern Italy
were targeted for populational genetic studies based on their unique
gene pool 93 These villages have existed relatively undisturbed for
thousands of years. 94 In fact, many of them had no roads or
86

Michael Tarm, Estonian ParliamentApproves Plan to Set Up National Gene Bank,

AP NEWSWIRES, 13:12:00, Dec. 14, 2000.
87

Id.

88

Michael Gross, EstoniaSells Its Gene Pool: A Genetic DatabaseProject is an Ethical

Timebomb, GUARDIAN, Nov. 9, 2000, available at 2000 WL 29261389.
89 Tarm, supra note 86.
90 Robin McKie & Patrick Wintour, Ethics FearOver Mass Gene Bank: Britain to Stage
World's Largest Clinical Trial to Help Pharmaceutical Companies Develop New Drugs,
See also Dominic Tonner,
Ethics FearOver Gene Bankfor Medical Trials, SUNDAY TIMES (London), Feb. 13, 2000, at 12,
available at 2000 WL 7085311.
91 McKie, supra note 90.
92 Tonner, supra note 90.
93 Rory Carroll, Meet the Inhabitants of Genetic Park: Centuries of Isolation Have
OBSERVER, Feb. 13, 2000, at 1, available at 2000 WL 7007034.

Turned the Inhabitantsof Remote Italian Villages Into a Living Laboratory,GUARDIAN, Oct.
30, 2000, availableat 2000 WL 28880578. See also Tom Hundley, Remote Italian Town on the
Mapfor Geneticists: Clues to Disease are Sought, CHI. TRIB., Dec. 31, 2000, at 1, available at
2000 WL 29792491.
94 Carroll, supra note 93; Hundley, supra note
93.
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electricity until fairly recently. 95 Their isolation has created an
extremely homogenous gene pool that researchers trust is very
valuable. 96 A team from the International Institute of Genetics and
Biophysics, a division of the Italian National Research Council, 97 has
already begun the collection of genealogical data in Gioi, Cilento, and
other remote Italian villages, and the collection of DNA samples will
commence soon. 98 Unlike other targeted populations, the residents of
this remote region have not raised concerns over their privacy or the
manner in which their data will be used.99 Instead, the residents have
embraced the project in hopes of increasing tourism and employment
opportunities for local residents.100 Like several other projects, the
Italian National Research Council is contributing only part of the
funding for the project. It is hoped that private companies interested
in the data will provide additional financing to complete the
project. 101
In late November 2000, it was announced that an Australian
based company, Autogen, acquired the exclusive right to a database
being developed in the South Pacific nation of Tonga. 10 2 The
Tongans have also enjoyed relative isolation for many years and their
population of 108,000 inhabitants consists primarily of Polynesian
descendants. 10 3 Autogen said that under its deal with the Tongan
government, participation in the study will be strictly voluntary and
all data collected will remain government property. 1 4 In exchange
for use of the data, Autogen will also set up a major research facility
on Tonga that will provide the local residents with jobs and the
company agreed to pay royalties to the government on any
discoveries that eventually may be commercialized. 10 5

95 Carroll, supra note 93; Hundley, supra note 93.
96 Hundley, supra note 93.
97 See Istituto Internazionale di Genetica e Biofisica [International Institute of Genetics
and Biophysics], at http://www.iigb.na.cnr.it (last visited October 27, 2001).
98 Carroll, supra note 93.
99 See id.; Hundley, supranote 93.
100 Carroll, supra note 93.
1 Id.
102 Deborah Smith, Tongans Sell Rights to DNA Data, SYDNEY MORNING HERALD, Nov.
23, 2000, at 3, availableat 2000 WL 28718543.
103

Id.

104

Id.

105

Id.
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D. ProposedStudies in the United States
Several similar projects have been proposed or begun in the
United States as well. One failed proposal would have expanded the
research data already collected by the Framingham Heart Study,
which has been collecting medical data on the residents of
Framingham, Massachusetts since 1948.106 Boston University, in
partnership with a group of venture capitalists, founded a company
called Framingham Genomic Medicine to reorganize the data already
collected from over 10,000 participants and supplement it with
additional DNA information.1 07 However, the deal was cancelled in
December 2000 after negotiations broke down. 0 8 One major point of
contention was the University's desire to continue making its research
data, which was collected using public funds, freely available to
nonprofit researchers, whereas the company planned to generate
profits by selling access to the data to commercial enterprises.10 9 The
two sides were unable to reach an agreement satisfying both goals,
thus highlighting one common battle in population-based studies
relying on both public and private funding.
In August 2000, a California company, DNA Sciences, launched
a Web site designed to attract potential participants for its research
efforts. 10 The company relies on altruistically motivated volunteers
to participate."' Under the DNA Sciences approach, volunteers are
asked to answer a series of on-line questions about family and
medical history. 1 2 Following completion of the survey, the volunteer
is contacted if his or her profile matches any of DNA Sciences'
current studies so that a blood sample may be collected. 1 3 DNA
Sciences hopes to attract between 50,000 and 100,000 volunteers

106

Antonio Regalado, Firm Set to Mine Framingham HeartStudy, TECH. REV., Jul./Aug.

2000,107at 26, 26, available at 2000 WL 11628580.

Id.

108

Naomi Aoki, BU Cancels Deal to Sell Patient Data, BOSTON GLOBE, Dec. 29, 2000,

at Cl, availableat 2000 WL 3357452.
109 Id.
110 Andrew Pollack, E-Finance: Gene Hunters Say Patients are a Bankable Asset,
GUARDIAN, Aug. 2, 2000, available at 2000 WL 25042876.

See also DNA SCIENCES, at

http://www.dna.com (last visited Oct. 27, 2001) (providing basic information about the goal of
the DNA Sciences data collection project as well as the online consent forms and medical
history questionnaires being used by the company).
.. 1 Pollack, supra note 110.
112

Id.

Id.
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Information collected from the
through its on-line efforts.' 14
volunteers will then be available to various pharmaceutical and
biotechnology companies willing to purchase access to the data for
use in their own research projects.
In a similar venture, but using a different appeal, a Chicagobased company, First Genetic Trust, opened its doors in October
2000.115 Rather than appealing to a participant's altruism, First
Genetic Trust stresses its commitment to maintaining the privacy and
confidentiality of genetic information by leaving the power to control
the data and its use in the hands of each individual participant. 1 6 The
company plans to function as an intermediary between researchers,
healthcare providers, and patients by supplying educational and
counseling services, as well as a secure DNA "banking," or storage
service, thus balancing the privacy of the individual with the need for
researchers to have access to crucial populational data." 7
Other similar projects in the earliest stages of development are
announced almost monthly. Each study is aimed at developing
immense databases of information that may be used by researchers to
understand the intricacies of genetic diseases. 1 8 This information
will also be used by pharmaceutical companies to develop more
accurate genetic tests, more effective gene therapies directed at
treating and curing various disorders, and, eventually, the
development of drugs and treatments specifically designed for
individual patients based on their unique genetic makeup.' 9 To reach
that goal, mountains of data will need to be collected and analyzed.
Understandably, genomic research represents billions of dollars in
both investment costs to create the databanks and potential profits for
the companies who maintain and access the databanks.
E.

Challengesto Informed Consent and Confidentiality

During the course of any population-based genetic research,
those doing the data and sample collection must ensure that research
Id.
115

Paul Merrion, EntrepreneurSeeks Human Datafor First Genetic Trust, CRAIN'S CHI.

Bus., Oct. 30, 2000, at 12, available at 2000 WL 8129893. See also FIRST GENETIC TRUST, at
http://www.firstgenetic.net (last visited Aug. 16, 2001) (providing information about the
company's mission, products, and services).
116 Merrion, supranote 115.
117 See id.
118 See Peltonen, supranote 6.
119

See Robertson, supranote 20, at 60.
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subjects provide their informed consent based on a clear
understanding of the purpose of the project and their role as research
subjects. 12' These subjects will need to be informed clearly as to how
their information will be used and what safeguards are in place to
protect their privacy. 12 1 Researchers need to provide the subjects with
a clear statement enumerating the goals of the various projects,
including the diseases being studied and the identities of the various
entities, both public and private, that will be conducting the
research.12 2 Additionally, researchers need to adopt clear operating
policies regarding confidentiality of patient records. 2 3 Once the data
has been collected, further specific safeguards must be in place to
124
assure the continued confidentiality of individual subject records.
These informed consent and confidentiality issues will need to be
addressed in light of both the national laws where research is
conducted and any applicable international laws or treaties.
IV. INTERNATIONAL LAW RELATED TO BIOMEDICAL RESEARCH

Securing informed consent and maintaining confidentiality of
personal information concerning research subjects are of paramount
importance in any population-based study. For each of the studies
discussed above, there are, or should be, national laws governing the
studies,125 and in the case of the United States, state laws 126 governing
proper methods of securing effective informed consent and detailing
safeguards which
must be followed in maintaining medical and
27
1
records.
genetic
120 Id. at 61. See also TOM L. BEAUCHAMP & JAMES F. CHILDRESS, PRINCIPLES OF
BIOMEDICAL ETHICS 142 (4th ed. 1994).
121 See BEAUCHAMP, supra note 120, at 142, 418.
122 Id. at 142-46.
123 See id. at 418-29.
124 See id.
125 See David Banisar & Simon Davies, Global Trends in Privacy Protection: An
InternationalSurvey of Privacy, DataProtection and Surveillance Laws and Developments, 18

J. MARSHALL J. COMPUTER & INFO. L. 1 (1999) (providing an excellent survey of international
privacy laws from many nations related to all forms of personal privacy).
126 See Joy Pritts et al., The State of Health Privacy: An Uneven Terrain (A
Comprehensive Survey of State Health Privacy Statutes), in FIRST ANNUAL INSTITUTE ON
PRIVACY LAW: STRATEGIES FOR LEGAL COMPLIANCE IN A HIGH TECH AND CHANGING
REGULATORY ENVIRONMENT, 621 (PLI Pat., Copyright, Trademark, & Literary Property

Course, Handbook Series No. 607, 2000), WL 607 PLIPAT 621 (providing a detailed survey of
applicable state laws related to privacy of health records, including genetic information).
127 A full survey of all applicable national and state laws is beyond the scope of this
Comment and discussion in this section will be limited primarily to international laws and
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A.

UnitedNations and Human Rights

As in many areas of international law, the United Nations has
played a pivotal role in the protection of human rights. Until recently,
human rights protection in relation to scientific research, and
particularly genomic research, was based primarily on generalized
laws applicable to a wide range of human rights. The principle
starting point for the protection of human rights is found in the
International Bill of Human Rights, 128 consisting of the Universal
Declaration of Human Rights; 129 the International Convention on
Economic, Social, and Cultural Rights (ICESCR); 130 and the
International Covenant on Civil and Political Rights (ICCPR). 13 ' All
of these instruments, while drafted in general terms, contain
provisions that can be applied to the Human Genome Project. First,
each instrument emphasizes respect for human dignity. 132 In addition
to this general tenet, there are provisions related to general scientific
research that will apply to genomic research. In particular, ICCPR
article 7 declares that, "no one shall be subjected without his free
consent to medical or scientific experimentation."'' 33 This provision
provides a basis for many of the international codes related to
informed consent and human experimentation.
In light of the provisions related to human dignity, there are also
provisions strongly supporting the progress of scientific research.
Two provisions of the ICESCR are worth particular mention. Article
12 recognizes "the right of everyone to the enjoyment of the highest
attainable standard of physical and mental health."'' 34 In addition,
article 15 recognizes a right of everyone "to enjoy the benefits of
treaties which may govern some of these projects, although in Section V specific attention will
be paid to Iceland's Act on a Health Sector Database and the Estonian Human Genes Research
Act in comparison with other international laws discussed here.
128 InternationalBill of Human Rights, U.N. GAOR, 3d Sess., Supp. No. 1, at 71, U.N.
Doc. A/565 (1948).
129 UniversalDeclarationof Human Rights, G.A. Res. 217A(III), U.N. GAOR,
3d Sess.,
U.N. Doe. A/810 (1948) [hereinafter UniversalDeclaration].
130 InternationalCovenant on Economic, Social and Cultural Rights, G.A. Res. 2200,
U.N. GAOR, 21st Sess., Supp. No. 16, at 49, U.N. Doc. A/6316 (1966) [hereinafterlCESCR].
131 InternationalCovenant on Civil and Political Rights, G.A. Res. 2200, U.N.
GAOR,
21st Sess., Supp. No. 16, at 52, U.N. Doe. A/6316 (1966) [hereinafterlCCPR].
132 See Universal Declaration,supra note 129, art. I ("All human beings are born free
and equal in dignity and rights."). See also ICESCR, supra note 130, at preamble; ICCPR,
supra note 131, at preamble (both of which begin: "Recognizing that these rights derive from
the inherent dignity of the human person . .
133 ICCPR, supra note 131, art. 7.
134 ICESCR, supra note 130,
art. 12.
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scientific progress and its application," while respecting "the freedom
indispensable for scientific research and creative activity."' While
these provisions clearly provide support for scientific freedom in
research, they must be carefully balanced against the rights of the
individuals stressed throughout the other instruments comprising the
Universal Bill of Human Rights.
B. UNESCO Declarationon the Human Genome and Human
Rights
In 1997, the United Nations Educational, Scientific, and Cultural
Organization (UNESCO) drafted the Universal Declaration on the
Human Genome and Human Rights 136 (the "Declaration") to address
many of the issues specifically related to genetics research. It is clear
from this instrument that UNESCO believes genomic research to
impinge upon a unique set of human rights worthy of separate
consideration:
Recognizing that research on the human genome and the
resulting applications open up vast prospects for progress in
improving the health of individuals and of humankind as a
whole, but emphasizing that such research should fully
respect human dignity, freedom and human rights, as well as
the prohibition of all 37forms of discrimination based on
genetic characteristics. 1
While meant to be a comprehensive instrument dealing with genetic
research, it has been criticized for being vague in defining several of
embryo
its terms and failing to address key issues such as human
38
research, genetic enhancement, and reproductive autonomy.
Despite that criticism, there are several provisions related
directly to the conduct of genomic research. First, article 10 states
that respect for human rights, fundamental freedoms, and dignity

135

Id. art.15.

136

UniversalDeclarationon the Human Genome and Human Rights, U.N. Educational,

Scientific and Cultural Organization [UNESCO], 29th Sess., 29 C/Resolution 19 (1997)
[hereinafter Genome Declaration]. See The Human Genome and Human Rights, U.N. Res.
53/152, 53d Sess., Agenda Item 110(b), U.N. Doc. A/RES/53/152 (1999) (endorsing
UNESCO's Genome Declarationin 1999).
137 Genome Declaration,supranote 136, preamble (emphasis in original).
138

Allyn L. Taylor, Globalization and Biotechnology: UNESCO and an International

Strategy to Advance Human Rights and Public Health, 25 AM. J.L. & MED. 479, 510-11

(1999).
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should prevail over any genetic research. 139 Article 12 then supports
freedom of research that seeks to "improve the health of individuals
and humankind as a whole."' 40 However, other than article 11, which
specifically prohibits human cloning,' 4 ' the individual member
nations are left to determine which research should be allowed and
which should be prevented. In fact, article 15 directly supports this
conclusion and provides only one clear restriction: research should
142
not be conducted for "non-peaceful purposes."'
Other articles of the Declaration provide guidance to the research
community regarding the development of research protocols. Article
5 requires that free and informed consent be given by any research
subject, 143 provides for prior review of all research protocols,' 44 and
protects individuals who lack the capacity to consent to research from
4
being included in studies where they will not directly benefit. "1
However, although article 5 requires prior review of research
protocols, it does not establish any standards for review other than
"accordance with relevant national and international research
146

standards or guidelines."'
One area receiving only minor attention in the Declaration
concerns confidentiality of the medical and genetic records of the
research participants. In the types of studies being proposed, several
unique databases are often employed: one database for genetic
information, one for genealogical information, and one for individual
medical history information. 47 In order for research goals to be met,
personal information from all three databases must be accessed and
provided to the research community. Researchers need to be able to
look at an individual's genetic information in the context of that
individual's family and personal medical history. Therefore, there
139 Genome Declaration,supranote 136,
art. 10.
140

Id. art. 12(b).

141 Id. art.
11.
142 States should take appropriate steps to provide the framework for the free exercise of

research on the human genome with due regard for the principles set out in this Declaration, in
order to safeguard respect for human rights, fundamental freedoms and human dignity and to
protect public health. They should seek to ensure that research results are not used for nonpeaceful purposes.
Genome Declaration,supra note 136, art. 15.
143 Genome Declaration,supra note 136, art.
5(b).
144 Id. art. 5(d).
145 Id.art. 5(e).
146 Id. art.
5(d).
147 See Greely, supra note 20, at
161-62.
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must be a method for correlating information from one individual
among all three databases while maintaining confidentiality of
individual records. Although article 7 of the Declaration requires that
"[g]enetic data associated with an identifiable person" must be held
confidential,1 48 it makes no mention of genetic data on which
personally identifiable data has ostensibly been removed, perhaps
having been replaced by an encrypted access key to maintain the
correlation between the databases. It is unclear whether any right of
confidentiality should be extended to such "non-identifiable" data.
C. European Union Laws Related to Privacyand Medical
Research
In addition to the United Nations, the European nations, through
both the Council of Europe and the European Union, have played an
important role in shaping international law. One of the pivotal
instruments issued by the Council of Europe related to genomic
research is the Convention on Human Rights and Biomedicine (the
"Convention"). 149 In article 2, the basic supremacy of the individual
cited in the United Nations instruments is reiterated. 50 However, the
Convention then seeks to provide clear guidelines for carrying out
scientific research in a manner consistent with preserving those
fundamental human rights as stated in the explanatory notes
underlying article 15:
Freedom of scientific research

. . .

is justified not only by

humanity's right to knowledge, but also by the considerable
progress its results may bring in terms of the health and
well-being of patients.
Nevertheless, such freedom is not absolute. In medical
research it is limited by the fundamental rights of individuals
151

In particular, article 16 enumerates specific requirements that must be
met before research on human subjects can commence. 152 These
requirements include ensuring that risks to the individual do not
148

Genome Declaration,supra note 136, art. 7.

149 Council of Europe, Convention on Human Rights and Biomedicine and Explanatory

Report, April 4, 1997, 36 I.L.M. 817 [hereinafter Convention on Biomedicine] (signed by
twenty-two member states).
150 Id. art. 2.
151
152

Id. at 835 nn.95, 96.
Id. art. 16.
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outweigh the potential benefits of the research, 153 receiving
plans,
including
independent
approval
of all
research
multidisciplinary review, 154 and ensuring that research subjects have
been fully informed of both their rights and the safeguards used to
protect their information.' 55
This final provision is further
strengthened by article 16(v), requiring that a research subject must
provide express, specific, documented consent that may be withdrawn
Satisfaction of these requirements is often
at any time. 56
accomplished by the passage of all research proposals through a
scientific review board at either the institutional or governmental
level.157 A key aspect of article 16(v) for projects related to genetic
and medical databases, where the information will be maintained for
long periods of time and accessed by many different users, is the
ability of a research subject to opt out of a project even years after the
initial data collection has been completed.
In addition to the Convention on Human Rights and
Biomedicine, the European Union has also adopted a Directive
concerning the processing of personal data that provides valuable
guidance for the creation of the genetic and medical databases
necessary for population-based research.1 58 In the Directive, personal
data is specifically defined as "any information relating to an
identified or identifiable natural person, ''1 59 and includes specific
reference to physical and physiological factors that may be used as
identifiers. 160 The unique DNA sequence of an individual satisfies
this definition, thus allowing genetic information to fall within the
scope of the Directive.
Under the Directive, personal data may only be "collected for
specified, explicit and legitimate purposes,"'' 6 and must be
153 Id. art. 16(ii).

154

Id. art. 16(iii).

155 Convention on Biomedicine, supra note 149, art. 16(iv).
156 Id. art. 16(v).
157 Robertson, supra note 20, at 70.

158

Council Directive 95/46 of 24 October 1995 on the protection of individuals with
regard to the processing of personal data and on the free movement of such data, 1995 O.J. (L
281)

available at http://europa.eu.int/eur-lex/en/lif/datl1995/en_395L0046.html

31,

updated Mar. 11, 1999) [hereinafter Council Directive 95/46].

(last

See also Fred H. Cate, The

ChangingFace of Privacy Protection in the European Union and the United States, 33 IND. L.

REv. 173 (1999).
159 Council Directive 95/46, supra note 158, art.
2,
160

Id.

161

Id.art. 6, l(b).

1(a).
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accompanied by the unambiguous consent of the subject. 162 These
general provisions are further restricted in regard to certain classes of
data, including medical records. 163 Further provisions of the Directive
enumerate what must be disclosed in obtaining consent to collect
data, 164 provide the subject with rights to access and correct
information, 165 and iterate the security guidelines and safeguards
which must be maintained to protect the data. 166 This Directive lays a
solid foundation for the data collection and processing which will be
required for the success of population-based research. When viewed
in combination with the Convention on Human Rights and
Biomedicine, the European Union has progressed well beyond the
general tenets expressed in the United Nations' Covenants and
Declarations in protecting individual genetic and medical
information.
Obviously, not all nations in which population-based studies are
proposed are subject to either United Nations or European Union
regulation. Nevertheless, the influence of these two organizations
often extends beyond their member nations and, thus, the materials
discussed herein provide an appropriate starting point for analysis of
any national laws specifically enacted to authorize the collection and
use of genetic and medical data for the purposes of creating
population-based databases.
V. ANALYSIS OF SPECIFIC LEGISLATION DIRECTED TO POPULATIONBASED GENETIC STUDIES

Among the projects discussed in Part III, two host-nations have
enacted specific legislation authorizing the creation of national
databases to be used for genetics research: Iceland's Act on a Health
Sector Database 167 and Estonia's Human Genes Research Act. 168 The
Icelandic project has been the source of much controversy and debate.
Much of the criticism directed at the project centers around general
inadequacies of the Icelandic Act and the intermingled relationship
162

Id. art. 7,

163

Id. art. 8.

1(a).

164 Id. art. 10.
Council Directive 95/46, supranote 158, art. 12.

165

166

Id.arts. 16-17.

167

Health Sector Database Act, supra note 80.
Human Genes Research Act, RIIGI TEATAJA [STATE GAZETTE] I 2000, 104, 685

168

(Est.), availableat http://www.genomics.ee/genome/act 13l2.html (Dec. 29, 2000).
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between the government and private industry.' 69 In addition to the
Act on a Health Sector Database itself, Iceland also enacted
Government Regulation 32/2000, attempting to codify the procedures
described in the Act. 170 The second nation to have newly enacted
laws directly related to the creation of a national genetic and medical
database is Estonia. 171 In December 2000, the Estonian Parliament
passed the Human Genes Research Act. 172 For purposes of this
Comment, discussion will be limited to the provisions of these two
national laws related to informed consent and confidentiality of
individual data.
A.

Basic Tenets of Informed Consent

Five basic elements have been identified that must exist for there
to be informed consent in any medical-related project: (1)
competence, (2) disclosure, (3) understanding, (4) voluntariness, and
(5) consent. 173 Based on these elements, informed consent is effective
only if the person from whom consent is sought is sufficiently
competent to comprehend fully the information being disclosed
concerning the procedure involved in data collection, the nature of the
research being conducted and the uses which will be made of any data
collected. 174 As part of the disclosure, the subject must have all of his
or her questions satisfactorily answered and must ultimately consent
voluntarily to the collection of data. 175 These tenets help to clarify the
consent requirement found in the
European Union Convention on
76
Human Rights and Biomedicine. 1
1. Informed Consent and Iceland
Iceland's Act on a Health Sector Database (the "Icelandic Act")
has received strong criticism for its lack of informed consent
169
170

See generally Greely, supra note 20, at 176-91; J6natansson, supra note 75, at 42-57.
Government Regulation No. 32/2000 on a Health Sector Database (2000) (Ice.) at

http://government.is/interpro/htr/htr.nsf/pages/Govreg32-2000 (Jan. 20, 2000) [hereinafter
Government Regulation No. 32/2000].
171
Tarm, supranote 86.
172 Id. Interestingly, in the 101-seat legislature, the Act was passed by a vote of only 42to-3. One member abstained and the rest either did not vote or were not present.
173

BEAUCHAMP, supra note 120, at 145.

See id. at 143.
175 See id. at 147.
176 Convention on Biomedicine, supra note 149, art. 16.
174

accompanying notes 152-56.

See also supra text
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provisions. 177 In fact, the Icelandic Act specifically provides that
mere consent from health institutions and practitioners who maintain
patient medical records will suffice for information to be included in
the database. 178 To have information excluded, a patient must make a
specific, affirmative request to opt out of the database. 179 These
provisions are tantamount to presumed consent unless otherwise
notified, and are clearly contrary to international standards espoused
by the United Nations and the European Union. 80 Such a notion is
even more troubling when it is considered in light of Icelandic
statutes related to patient rights 181 and biobanks 182 which clearly
require that free, informed consent be given prior to collection of any
biological samples to be used for scientific research. 183 The situation
is further muddied by the regulation issued to establish guidelines for
the creation and operation of the database. The regulation maintains
the opt out standard 84 but contrarily states that:
The collection, transfer and processing of data in the Health
Sector Database shall at all times be conducted in full
compliance with recognised international rules on science
ethics and rules established
on their basis and current in
185
Iceland at any time.
It is difficult to reconcile this final provision, which would
require compliance of the patient right and biobank statutes, with the
presumed consent provisions. Clearly, Icelandic law in other healthrelated areas requires informed consent similar to that expected by the
United Nations, the Council of Europe and other bodies that have
provided relevant guidelines. One possible explanation for the
disjunction between the Icelandic Act and other Icelandic statutes is
that this Act was heavily influenced by deCode Genetics' CEO Karl
186
Stefansson, the first licensee authorized to administer the database.
Greely, supranote 20, at 178.
Health Sector Database Act, supra note 80, art. 7.
Id. art. 8.
180 See supra Part IV.
181 Act on the Rights of Patients No. 74/1997
177

178

art.

10

(1997)

(Ice.),

at

http://govemment.is/interpro/htr/htr.nsf/pages/act-rightspatients (May 28, 1997) [hereinafter
Patients' Rights].
182 Act
on
Biobanks
No.
110/2000
art.
7
(2000)
(Ice.),
at
http://govemment.is/interpro/htr/htr.nsf/pages/Act-biobanks (May 13, 2000).
183 Id. art. 7; Patients' Rights, supranote 181, art. 10.
184 Government Regulation No. 32/2000, supra note 170, art. 12.
Id. art. 6.
186 See generally Greely, supra note 20, at 176-91.

82 COMPUTER & HIGH TECHNOLOGY LA WJOURNAL

[Vol. 18

In fact, the government has acknowledged that deCode provided the
initiative for the Icelandic Act.18 7 This makes sense given the fact
that deCode could enjoy immense savings of both time and money
expended on data collection if the presumed consent model is
maintained.
Iceland is not yet a member of the European Union, which
means they are not formally required to implement Directives of the
European Union. However, a group opposed to the Icelandic Act,
known as Mannvemd, has filed a formal complaint before the
European Free Trade Area Surveillance Authority, which regulates
various trade practices of the countries of the European Economic
Area, of which Iceland is a member. 8 1 If the Mannvemd is
successful in its complaint, then Iceland would need to redraft its Act
to provide an internationally acceptable opt-in program based on
securing prior, effective, informed consent before any information is
placed in the database.
2.

Informed Consent and Estonia

In contrast to the controversial legislation in Iceland, the
Estonian Human Genes Research Act' 89 (the "Estonian Act") contains
several provisions focusing on the rights of research subjects. First,
there is an extensive provision related to informed consent requiring
that full, voluntary informed consent must be given prior to any
collection of data.1 90 Furthermore, specific disclosures must be part
of the consent such as identification of the physician taking the
sample, specific identification of the procedure to be used in taking a
sample, and an enumerated list of rights which the subject maintains
following collection of the sample.' 91 The other rights which research
subjects are granted under the Estonian Act include the right to
disclose or not disclose their status as research subjects, 92 the right to
free personal access to their records in the database,' 93 the right 1to
94
genetic counseling to aid the subject in understanding their data,
and the right to have all personal data capable of being decoded
187

See J6natansson, supra note 75, at 37.

188

Greely, supra note 20, at 175.

189
190

Human Genes Research Act, supra note 168.
Id. § 12(1).

191 Id. § 12(3).
192 Id.§8.
193 Id. § 11(4).
194 Id
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destroyed, or, in the case of unlawful access
by others, the right to
95
data.'
personal
all
of
destruction
request
The provisions of the Estonian Act far surpass the vague
language and generalized recommendations of the UNESCO
Universal Declaration on the Human Genome.196 In fact, the Estonian
Act provides an appropriate model for compliance with the European
' 97
Council Convention. The "prior, free and informed consent"'
required by both the Declaration and the Convention is clearly
established and its elements enumerated by the Estonian legislation.
3.

Several Informed Consent Questions Remain
Unanswered by Present Legislation

At this time, some questions remain unanswered by both the
Icelandic and Estonian regulations. The purpose of the populationbased databases is to provide information and data to various entities
ranging from nonprofit research organizations to pharmaceutical and
biotechnology companies.' 98 In turn, each of these organizations will
seek access to different types of data and for different research
purposes. Under the European Convention on Human Rights and
Biomedicine and the Estonian Human Genes Research Act, informed
consent is to be specific with regard to the purposes of the research. 199
An obvious issue arises as to whether it is possible to satisfy these
disclosure requirements with a blanket consent given at the time of
data collection, which states that samples are to be used for genetic
research in general with a list of the various types and methodologies
of research to be pursued, or whether consent needs to be renewed
upon specific disclosure of the research to be pursued by each new
entity seeking access to the data. While the notion of specific
informed consent and supremacy of the human being may favor the
latter, such a system would be extremely burdensome and expensive
for those who maintain and access the databases.200 The former
method, whereby a single consent secured at the outset of the
collection which could be sufficient to cover all potential research
195
196
197
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situations, is much easier to implement and maintain, but may violate
the specific disclosure requirements of some statutes. Perhaps the
best method would be a combination of the two approaches: initial
consent is provided at the outset, but periodic notification is provided
to research subjects detailing access requests and uses of the database.
In extreme cases where access is sought that would depart
substantially from the types of research initially enumerated, it may
be desirable for renewed consent to be obtained.2 1 Under this mixed
approach, the scientific community saves time and money that would
be necessary to secure renewed consent for every individual research
project and the research subjects benefit by being informed of
ongoing research projects. It has been said that silence breeds
mistrust, and mistrust of the scientific community is rampant in the
absence of clear communication. By providing periodic updates and
notices concerning research being pursued using the databases, the
population may feel more secure with the research. Such security
could ultimately benefit the research community through an increase
in the number of people willing to submit their information to the
databases.
B. Confidentiality of Individual Data
As genetic, genealogical, and medical data is collected, it will be
entered into vast computerized databases so researchers may use it
effectively.20 2 Major concerns have been raised regarding access to
the information contained in these databases. 0 3 While absolute
security of the information is unrealistic, each project should have
clearly established guidelines to provide maximum protection for
individual information while not unduly burdening scientific freedom.
Those guidelines must address the treatment of personally identifiable
information potentially contained in the records, identification of the
government and private entities accessing the databases, and
safeguards employed to prohibit unauthorized access.
Due to the very nature of the information necessary for medical
research, population-based health databases present unique
confidentiality problems. A data subject's name and any identifying
numbers may be removed from his data; but for purposes of some
studies, it will be important that researchers be able to locate and
201
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study records based upon region of birth and residence, date of birth,
or certain medical characteristics which are found in the records, such
as frequency of treatment for a given condition. 20 4 Even in the
absence of names, identifying numbers, or the other "normal"
identifiers, it may still be possible for someone to gather enough
information from the various databases to bring identification to a
virtual certainty. For example, in a sample of 100,000 individuals, if
someone searches the databases for males born in 1963 in a specific
town or county, who are between 5'9" and 6'0" tall, have one
younger brother and one older sister, whose mother died of breast
cancer, such information will greatly reduce the number of records
which will be returned. Much of the data listed above can easily be
derived from the basic medical history submitted by many people as
part of a standard visit to a physician for a physical, completion of a
basic health or life insurance application, or paperwork completed in
the course of securing employment. If enough basic information, all
of which may have a legitimate research justification for its inclusion,
is combined, individual records may be retrievable. Therefore, unless
access to the databases is carefully controlled, an insurance company
or employer could easily use the basic data provided by applicants
and employees, and use that information to extract the full records,
including the genetic profile, of the individual. Such access could
facilitate genetic-based discrimination in the workplace and the
insurance industry.0 5
As mentioned previously, the European Directive on the
Protection of Individuals with Respect to the Processing of Personal
Data defines a personally identifiable individual as one who "can be
identified, directly or indirectly . . . by reference to ... one or more
factors specific to his physical, physiological ... identity.'2 0 6 In the

realm of genetic research, however, the very information related to
physical and physiological identity is the information most necessary
for the database to have value to the research community.20 7
Therefore, it is imperative that the most stringent guidelines be
established to control maintenance of, and access to, these databases.
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1. Confidentiality and Iceland
The Icelandic Act on a Health Sector Database (the "Icelandic
Act") falls far short of providing the necessary safeguards to protect
the confidentiality of the research subjects. Although the Icelandic
Act includes provisions related specifically to the actions of 2the
08
licensee, requiring it and its employees to maintain confidentiality,
there are also noticeable conflicts and deficiencies in this Act. Article
3(2) of the Icelandic Act mirrors the definition contained in the
European Directive, but then also identifies non-personally
identifiable data as, "data on a person who is not personally
identifiable as defined in clause 2. ",209 Furthermore, the Icelandic Act
requires that all personally identifiable information entered in the
database shall be "one-way" encoded such that it cannot be traced
using a decoding key. 210 Commentators have rightly noted that this
provision cannot be read literally, as any such one-way encoding
would destroy the ability to add information to a research subject's
file or to link records between the separate genetic, genealogical and
medical history databases.21 '
Perhaps because of its failure to
recognize the actual necessity for decoding information in order to
add to records and link information, the Icelandic Act does not
mention who would control the decoding key: the licensee, a
government agency, or some third party. Since the licensee is
authorized to process the data,212 maybe the licensee should control
the key. However, since the government will be providing oversight
of the database,2 13 perhaps the government should control the key.
The combination of these various provisions illustrates that, at
the very least, the Icelandic Act provides conflicting guidelines,
possibly reflecting either a lack of forethought or the presence of
commercial pressures during the drafting of this Act.
The
information necessarily excluded under the definitions is the very
information the Icelandic Act is designed to collect. Additionally, the
necessary processing of the data for research automatically violates
the Icelandic Act itself since any linking between databases ultimately
208
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relies on some "identifiable" marker to provide that necessary link.
Rather than providing any meaningful clarification of the Icelandic
Act itself, the Regulation designed to implement the Act simply
demands that the licensee operate the database in accordance with the
Acte21 4 and in cooperation with the Data Protection Commission, an
oversight committee of the government.2 15
2. Confidentiality and Estonia
Unlike the Icelandic Act, the Estonian Human Genes Research
Act (the "Estonian Act") clearly recognizes the need for linking data
in the genetic, genealogical, and medical databases. Rather than
having the database maintained by a commercial licensee, the
Estonian Act designates to manage the database a "chief processor,"
defined as "a non-profit foundation founded by the Republic of
Estonia" within the Ministry of Social Affairs.216 In addition, all
coding and decoding functions must be maintained and performed by
the chief processor and may not be delegated to outside parties. 217
Beyond simply appointing a separate government agency to maintain
the gene bank, other provisions further restrict access by researchers.
For instance, genealogies may only be used within the gene bank to
arrange tissue samples, DNA information, and health information
according to blood relationships; researchers themselves are not
allowed direct access to this information.2 18 Any issuance of linked
samples consisting of tissue samples, DNA information, and medical
information may only be done in batches containing information from
at least five donors whose data satisfies the selection criteria
established by the researcher. 219 This provision represents an attempt
by the Estonian government to reduce the risk of actual identification
of a research subject while still meeting the need for accurate
information required by the researcher. Although no system will
completely eliminate the potential identification of a research subject,
the Estonian Act represents a conscientious attempt to balance the
needs of both parties.
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The Estonian Act, unlike the Icelandic Act, provides clear
guidelines concerning encoding 220 and decoding 22 1 information within
the database. Under the guidelines, the only identifiable link between
sets of data will be the randomly generated sixteen-character
encryption label provided and maintained solely by the chief
processor. 22 In addition to the processing guidelines, section 24 of
the Estonian Act also enumerates the specific instances in which the
chief processor may authorize the decoding of any information.223
According to the Estonian Act, the chief processor may only decode
information in the following situations: where it is necessary to
destroy samples provided to the gene bank;224 where the original

donor either personally, or through his doctor, has requested access to
the sample; 225 where the information needs to be renewed,
supplemented or verified; 226 where a tissue sample has been corrupted
and a new sample must be collected; 22 7 or where 228
it is necessary to
information.
new
on
based
data
amend genealogical
Although not perfect, the Estonian Human Genes Research Act
provides much clearer guidelines than the Icelandic Act on a Health
Sector Database. By recognizing that data must be encoded and
decoded, as well as linked, Estonia drafted relatively unambiguous
guidelines under which its chief processor must operate. These
guidelines represent an attempt to balance the demands of the
research community against the necessity of maintaining the
confidentiality of information provided by the research subjects.
Although further examination will be necessary to determine the
effectiveness of the legislation in meeting this goal, a framework is in
place to properly analyze new challenges as they arise.
As previously discussed, the Estonian Act anticipates the effects
of population size on confidentiality. The Estonian database is
expected to contain eventually over one million records from
individual donors.229
Statistical analysis may reveal that the
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likelihood of identification of a single donor from a group of five
records provided to a researcher is minuscule when drawn from such
a large population. Nevertheless, in order to maintain the same level
of anonymity in smaller populations, a larger pool of donors must be
provided to the researchers. In overly general terms, in a population
of one million, the chance that any one individual will be randomly
selected is only 0.0001%. However, in a population of 100,000, that
probability rises ten-fold. In other words, in order to maintain the
same anonymity of individuals from smaller populations, the number
of records disbursed at one time must also increase ten-fold. At some
point, if a population is small enough, the number of records that
must be provided at once to maintain anonymity may be so great as to
diminish the utility of those records to the researcher. While a pool of
five records is useful, a pool of forty or fifty may not be as useful
without the identification of specific linkages between each DNA
sample and its genealogical and medical data. When that point is
reached, new standards may be needed. Hopefully, the new standard
will favor increasing the size of the database rather than increasing
the risk that individuals may be readily identified from releasing only
a small number of records from a small population.
VI. PROPOSAL AND CONCLUSIONS

The Human Genome Project is reshaping the way we view
genetic traits and diseases. 230 Through continued research, genetic
testing will be available to pre-diagnose a multitude of genetic
conditions and treatments will be available to correct genetic
deficiencies, ultimately leading to increases in the quality and length
of life for many people.23 1 However, in order for these benefits to be
realized, researchers will need access to the most vital personal
information of thousands, even millions, of people.23 2 It has been
suggested that each of us as human beings may have a duty to
participate in research for the betterment of humanity. 233 DNA
Sciences asks people to remember friends and family members who
have been afflicted with disease and then to lend support to its
230
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research efforts by volunteering to donate DNA samples and medical
histories.234 After all, if we are to be the beneficiaries of the
advances, then we must be willing to contribute to those advances.
To act otherwise would be unjustly self-centered.23 5
This may be true, but before someone volunteers to act as a
research subject, he or she needs to have certain assurances in place.
First, all research subjects must be given complete information
concerning: the procedures they will undergo to provide samples; any
other information such as medical history and genealogic data which
will be collected; the purposes for which the information will be used;
and the safeguards which will be employed to protect the privacy of
that individual's very personal, private information. 236 Second,
whatever safeguards are employed to protect the identity of research
subjects must be clearly described and rigorously maintained.2 37
Many of the guidelines for such research will ultimately be provided
by legislation.
It has been shown that certain international materials, such as the
United Nations instruments directed toward the protection of human
rights,238 provide a general basis from which to begin, but are not
explicit enough to provide the necessary protections required by this
type of research. The European Council Convention on Human
Rights and Biomedicine 239 and the European Union Directive on the
Protection of Individuals with Regard to the Processing of Personal
Data 240 provide stronger direction than the United Nations
instruments, but still fall short when it comes to genetic information.
Ultimately, it will be the individual nations involved in this type of
research that must set their own guidelines. At a minimum, these
regulations must support the basic principles embodied in the
International Bill of Human Rights of the United Nations.241
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A. InternationalExpectationsfor Informed Consent and
ConfidentialityMust Be Honored
As of the writing of this Comment, two nations have pursued
legislation directly related to the creation of population-based genetic
databases: Iceland and Estonia.242 The Icelandic Act on a Health
Sector Database continues to be highly criticized. First, individuals
are presumed to have consented to be part of the database,243 in
contravention of international provisions, as well as of other Icelandic
statutes. 24 Second, safeguards to protect the identities of research
subjects are contradictory, impotent, or absent altogether.2 45 Because
of these deficiencies, the Icelandic plan should be reevaluated before
the project proceeds any further.
In contrast to Iceland's approach, the Estonian Human Genes
Research Act provides much better guidance for those interested in
pursuing or participating in genetic research. There are clearly
defined standards for encoding and decoding information vested in a
single authority.246 In addition, release of information to researchers
in pools of at least five donor samples 247 is designed to safeguard the
identity of the individual while still providing valuable information to
the researcher. It would behoove other proposed projects, and their
state sponsors, to study the Estonian Act closely and use it as a model
when drafting legislation and project guidelines. Of course, the
model will need to be modified for each proposed project.
B. CommunicationBetween Researchers and Research
Populationsis Essentialfor Success
In each instance, the interests of the researcher and the potential
benefit that may be reaped must be carefully balanced against the
interests of the individual in protecting the privacy of his or her
genetic and medical information. These goals can be met through
careful scrutiny of projects and proper planning. One key aspect of
this endeavor will be the enhanced communication between the
scientific community and the volunteer research subjects.
242
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First, it is recommended that all individuals be given the most
complete possible disclosure regarding their participation in a
research study. In these projects, where research is ongoing and
many different researchers and organizations will seek access to
information, such disclosure must also be ongoing. This does not
suggest that formal, written consent must be secured every time new
researchers seek access, simply that research participants should be
kept abreast of developments being made and pending requests for
access to their information. If a proposed project departs substantially
from the types of projects initially disclosed when consent was first
secured, then it may be desirable to provide a forum for the public to
express its concerns over proposed research, and, in certain cases,
require renewed consent before subsequent or continued access is
granted. Such procedures, especially requiring renewed consent, will
require that encoded information contained in the databases be
decoded in order to match the new consent with the records.
Fortunately for Estonia, and those that follow its model, the Estonian
Act contemplates, and appears capable of handling, such decoding
situations.
Second, each project must have a clearly delineated procedure
for the treatment of collected information. These protocols must
address how information will be encoded, who will maintain the
encryption/decryption keys, what specific occurrences will warrant
the decoding of information contained in the databases, who will have
access to each type of data and how that access will be granted, and
how information will be disbursed to researchers who request it. The
ultimate purpose behind each of these procedures is to reduce the risk
both of unauthorized access and identification of any particular
research subject based on his or her genetic or medical profiles. In
some cases, the size of the project itself will dictate certain procedural
strategies. This will be especially true in regard to the manner in
which information is distributed to the researchers. As mentioned in
Part III B., for a population of one million or more, the statistical
probability that any one individual will be positively identified from a
pool of five donors is very small. However, on Tonga where there
are only 108,000 inhabitants, or Iceland with 275,000 inhabitants, the
number of samples that must be disbursed together to reach an
acceptably low risk of positive identification may be much greater.
Procedures for each project must be adapted to that particular project.
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Population-based genetic studies are necessary to exploit fully
the potential provided by the Human Genome Project. In order to
achieve the greatest benefit while providing research subjects with the
greatest protections, extensive planning must be carried out before the
first sample is collected. Analysis of the scope of the project must be
done with an eye toward carefully balancing scientific freedom with
personal privacy. When this balance is achieved and maintained, then
people will be more inclined to contribute by participating in research
that will benefit us all.

